MICRO-ultrasound Guided Prostate SBRT

Starting soon · Not applicable

Conditions studied: Prostate Cancer

In brief

This study will test whether it is safe and effective to use stereotactic body radiation therapy (SBRT)-a short, targeted form of radiation-together with a microultrasound (microUS)-guided radiation boost to the cancerous spots inside the prostate. Researchers will compare treatment plans that use microUS to plans created using the current standard method, which relies on MRI images, to determine whether microUS can successfully guide targeted radiation.

Key facts

Study ID

NCT07737457

Run by

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

People needed

112

Starts

2026-09-01

Expected to finish

2033-03-01

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed carcinoma of the prostate (biopsy results with 12 months of enrollment)
• Intermediate risk as defined by NCCN criteria
• Conventional imaging (bone scan and abdominal pelvic computed tomography) is mandatory for NCCN unfavourable intermediate risk prostate cancer patients with PSA > 10. Negative nodal, skeletal or visceral metastases within 16 weeks of enrollment (for patients requiring staging). Alternatively, patients with no signs of extra-prostatic disease on PSMA-PET scans are also candidates for this trial
• ECOG performance status 0-1
• Willing to give informed consent to participate in this clinical trial
• Able and willing to complete QOL questionnaires Most responsive physician definition if androgen deprivation therapy will be used (only allowed for NCCN unfavourable intermediate risk prostate cancer)

You may not qualify if…

• Estimated prostate volume > 60cc (volume based on transrectal ultrasound)
• Prior TURP
• Prior prostate cancer treatment, including 5-alpha reductase inhibitor treatment
• Low, high or very high-risk disease as per NCCN guidelines
• Connective tissue disease or inflammatory bowel disease
• Contraindication to prostate microUS
• Men with double hip prostheses
• Contraindication for MRI (i.e. non-compatible stent, pacemaker, prosthesis etc.)
• Anticoagulation medication (if unsafe to discontinue for fiducial marker insertion)
• Diagnosis of bleeding diathesis

Where it is running

• London Health Sciences Centre, Verspeeten Family Cancer Centre — London, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.